Concordance and timing in recording cancer events in primary care, hospital and mortality records for patients with and without psoriasis: A population-based cohort study by Trafford, Alex M. et al.
RESEARCH ARTICLE
Concordance and timing in recording cancer
events in primary care, hospital and mortality
records for patients with and without
psoriasis: A population-based cohort study
Alex M. TraffordID
1*, Rosa Parisi2, Martin K. Rutter3,4, Evangelos Kontopantelis2,
Christopher E. M. Griffiths5, Darren M. AshcroftID
1, on behalf of the Global Psoriasis Atlas
(GPA)¶
1 Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health,
NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, United Kingdom,
2 Division of Population Health, Health Services Research and Primary Care, School of Health Sciences,
Faculty of Biology, Medicine and Health, NIHR School of Primary Care Research, University of Manchester,
Manchester, United Kingdom, 3 Division of Diabetes, Endocrinology and Gastroenterology, School of
Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre
(MAHSC), The University of Manchester, Manchester, United Kingdom, 4 Diabetes, Endocrinology and
Metabolism Centre, Manchester University NHS Foundation Trust, MAHSC, Manchester, United Kingdom,
5 Dermatology Centre, Salford Royal NHS Foundation Trust, Faculty of Biology, Medicine and Health, NIHR
Manchester Biomedical Research Centre, University of Manchester, Manchester, United Kingdom




The association between psoriasis and the risk of cancer has been investigated in numer-
ous studies utilising electronic health records (EHRs), with conflicting results in the extent of
the association.
Objectives
To assess concordance and timing of cancer recording between primary care, hospital and
death registration data for people with and without psoriasis.
Methods
Cohort studies delineated using primary care EHRs from the Clinical Practice Research
Datalink (CPRD) GOLD and Aurum databases, with linkage to hospital episode statistics
(HES), Office for National Statistics (ONS) mortality data and indices of multiple deprivation
(IMD). People with psoriasis were matched to those without psoriasis by age, sex and gen-
eral practice. Cancer recording between databases was investigated by proportion concor-
dant, that being the presence of cancer record in both source and comparator datasets.
Delay in recording cancer diagnoses between CPRD and HES records and predictors of dis-
cordance were also assessed.
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Results
58,904 people with psoriasis and 350,592 comparison patients were included using CPRD
GOLD; whereas 213,400 people with psoriasis and 1,268,998 comparison patients were
included in CPRD Aurum. For all cancer records (excluding keratinocyte), concordance
between CPRD and HES was greater than 80%. Concordance for same-site cancer records
was markedly lower (<68% GOLD-linked data; <72% Aurum-linked data). Concordance of
non-Hodgkin lymphoma and liver cancer recording between CPRD and HES was lower for
people with psoriasis compared to those without.
Conclusions
Concordance between CPRD and HES is poor when restricted to cancers of the same site,
with greater discordance in people with psoriasis for some cancers of specific sites. The use
of linked patient-level data is an important step in reducing misclassification of cancer out-
comes in epidemiological studies using routinely collected electronic health records.
Introduction
Psoriasis is an immune-mediated inflammatory disease, with substantial regional variation in
prevalence across the globe [1]. In Western Europe, the prevalence is relatively high when
compared to many other global regions, with UK-specific estimates that it affects 2.8% of the
general population [2]. The importance of psoriasis has been highlighted by the World Health
Organization (WHO) [3], which acknowledged not only the burden of the disease to the indi-
vidual and to society, but also the consequence of associated comorbidities. These comorbidi-
ties include psoriatic arthritis [4], cardiovascular disease [5], depression [6] and cancer [7]. As
in other diseases, many recent studies investigating comorbid conditions in psoriasis have
been conducted by using routinely collected electronic health records (EHRs). A recent sys-
tematic review [7] identified 37 studies examining the risk of cancer development in people
with psoriasis conducted using such databases, with many only utilising primary care [8–11]
or hospital [12–15] data. However, estimates quantifying the degree of risk remain varied. Sev-
eral explanations have been posited for this variation, including the extent of adjustment for
confounding and differing severities of psoriasis in study groups [16]. Whilst these explana-
tions may play a role, it is also important to consider, given the proportion of studies con-
ducted using EHRs, that some of the variation may come as a result of bias in the
ascertainment of cancer outcomes.
Population-based EHR databases present a number of distinct advantages for epidemiologi-
cal research, including increased power and consideration of multiple exposures [17], and
increasingly are being used to address questions related to dermato-epidemiology. Given that
such databases are derived from routinely recorded EHRs, it is important to consider the
potential for misclassification of outcomes. Recently, a cohort study using the Clinical Practice
Research Datalink (CPRD) found that the use of linked primary care and hospitalisation rec-
ords helped to avoid outcome misclassification, as the use of primary care data alone to ascer-
tain hospitalisation for lower respiratory tract infection would have underestimated the
incidence rate by 31% [18]. Given that a number of studies have investigated the risk of cancer
occurrence in psoriasis using only primary or secondary care data, it is important to consider
the extent to which misclassification may be a problem. The primary aim of this study was
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therefore to assess the concordance of cancer recording between primary care, hospital, and
national mortality records for people with and without psoriasis. Our secondary aim assessed
the delay in recording between the different data sources for same-site cancer records and risk
factors influencing discordance in recording.
Materials and methods
Data sources
Clinical Practice Research Datalink (CPRD) GOLD and Aurum. The CPRD is a UK-
based research service consisting of primary care records and formed from two databases:
GOLD and Aurum [19, 20]. Diagnostic information is recorded through Read codes, while
information on test results, ethnicity and lifestyle measures (e.g. smoking status) is also avail-
able. Data from registered patients in the contributing general practices in England may be
linked to a number of other data sources [21], including hospital records, in the form of Hospi-
tal Episode Statistics (HES) and mortality data, in the form of Office for National Statistics
(ONS) death registration data. Socioeconomic data is also available for linkage through the
Index of Multiple Deprivation 2010 (IMD), which is a small-area measure based on patient
residential postcode, providing an aggregate measure of deprivation across seven domains,
including income, employment and health [22].
Hospital Episode Statistics (HES). Hospital episode statistics consist of records from
inpatient, outpatient and emergency admissions in English NHS hospitals. Following patient
discharge, clinicians complete a discharge summary that is then entered into an electronic
patient information database. HES records contain a range of information, including patient
demographics (including ethnicity), medical diagnoses at discharge (coded using ICD-10) and
procedures (coded using OPCS-4) [23].
Office for National Statistics death registrations (ONS). ONS mortality records are
derived from death registrations. Upon patient death, an attending doctor completes a Medical
Certificate of Cause of Death (MCCD) that is then passed on to a local registrar of births and
deaths. Causes of death listed as part of a patients’ MCCD may be a primary or underlying
cause, and are coded according to ICD-9 (pre-2001) or ICD-10 (2001-present) [24].
Study population
Psoriasis patients were identified by a diagnostic Read code for psoriasis in the primary care
records within the study period (01/01/1998–30/11/2018). Patients were required to be eligible
for linkage to HES, ONS and IMD; be a minimum of 18 years old; and, have been in an ‘up to
standard’ practice (those with continuity in reporting of data and expected death rates) for at
least 12 months prior to study entry. Patients were excluded if they had any record of cancer
(excluding keratinocyte cancer) prior to study entry in order to ensure only primary cancers
were included. Additionally, patients with any diagnostic record of HIV/Aids prior to study
entry were excluded due to the associated increased cancer risk. A bridging file was applied to
the GOLD cohort to exclude patients and practices that transferred from CPRD GOLD to
Aurum. Cohort delineation is presented in S1 Fig. The index date for psoriasis patients was
defined as the first record of psoriasis in the study period.
Comparison patients were matched to psoriasis patients at a ratio of up to 6:1 on age, sex
and general practice. Restriction criteria for comparison patients were consistent with those
for psoriasis patients, with the addition of having no psoriasis record prior to study entry.
Pseudo-index dates for comparison patients were generated based on the index date of their
matched psoriasis patient. Psoriasis and comparison cohorts were identified separately for
CPRD GOLD and Aurum. All patients were followed from index date to the first occurrence
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of cancer diagnosis, transfer out from the general practice, last data collection date, study
period end or death.
Data analysis
Outcomes. The primary outcome of interest was cancer diagnosis. In order to examine
variation in concordance, cancer diagnoses were split into the following categories: all cancer
(excluding keratinocyte cancer), bladder, brain, breast, cervical, colorectal, gallbladder, Hodg-
kin’s lymphoma (HL), keratinocyte, kidney, laryngeal, leukaemia, liver, lung, malignant mela-
noma, multiple myeloma, nasal cavity, non-Hodgkin’s lymphoma (NHL), oesophageal, oral
cavity, ovarian, pancreatic, pharyngeal, prostate, stomach, thyroid and uterine cancer. Code
lists were formed by one author (AMT) and were then separately reviewed by two clinicians
(CEG and MKR), with any discrepancies rectified through discussion between both clinicians
and AMT. Code lists for exposure and outcome are available for download from www.
clinicalcodes.org [25]. Data analysis was carried out using Stata version 16 (Statacorp, College
Station, TX, USA).
Assessment of concordance. Concordance of cancer recording was considered between
one source database and a comparison database (i.e. CPRD as the source database with HES as
the comparison database, and vice versa). Records in the comparison database must have
occurred prior to transfer out date, last data collection date, study period end or death in order
to be eligible for consideration of concordance. Concordance between the source database and
the comparison database was classified into 3 groups: (1) same site recorded in the source and
comparison database (2) any cancer recorded in the comparison database (3) no record in the
comparison database. Additionally, for each cancer record in the source database, it was evalu-
ated whether there was any death registration including a record of cancer. Factors associated
with discordance in reporting between the source and comparison databases, for CPRD and
HES, were assessed using logistic regression. The following risk factors for discordance were
included in the model: age, gender, deprivation and time period. Where the same cancer-site
record was found in the comparison database, the delay in recording between the source and
comparison records was examined.
This study was approved by the Independent Scientific Advisory Committee (ISAC) for
Medicines and Healthcare Regulatory Agency database research (ISAC approval 19_089R).
Results
In CPRD GOLD, 58,904 people with psoriasis and 350,592 matched comparison patients were
included. In CPRD Aurum, 213,400 people with psoriasis and 1,268,998 matched comparison
patients were included (Table 1).
Concordance in cancer recording
The concordance of cancer recording between CPRD Aurum, HES and ONS is reported sepa-
rately for both people with psoriasis (Fig 1) and comparison patients (Fig 2). Concordance for
CPRD GOLD-linked data is reported in S2 and S3 Figs.
CPRD-identified cancer records. In CPRD Aurum, 11,889 and 63,691 cancers (excluding
keratinocyte) were identified in psoriasis and comparison patients respectively. Concordance
at the same site in HES was 71.0% for people with psoriasis and 71.5% for comparison patients.
Concordance for any record of cancer was higher (84.5% psoriasis; 84.8% comparison). In
CPRD GOLD, 2,916 and 15,236 cancers events (excluding keratinocyte) were identified in the
psoriasis and comparison group, respectively. Same cancer-site concordance with HES was
67.9% for people with psoriasis and 67.7% for comparisons. Concordance of any cancer record
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(excluding keratinocyte) was higher (82.7% psoriasis; 82.2% comparison). When examining
specific cancers, concordance between CPRD identified records and HES was lowest for kera-
tinocyte cancers and malignant melanoma in both CPRD Aurum and GOLD. In people with
psoriasis, for any cancer (excluding keratinocyte) record in CPRD, 35.2% (Aurum) and 35.3%
(GOLD) also had a cancer record in ONS mortality records.
Table 1. Demographic characteristics of psoriasis and comparison cohorts.
CPRD GOLD CPRD Aurum
Psoriasis cohort Comparison cohort Psoriasis cohort Comparison cohort
No. 58904 350592 213400 1268998
Female (%) 30301 (51.4) 180108 (51.4) 108539 (50.9) 644,353 (50.8)
Age, median (IQR) 47.2 (33.9–61.5) 47.1 (33.9–61.3) 45.9 (33.0–60.5) 45.7 (32.9–60.3)
Indices of Multiple Deprivation (%)
1 (least deprived) 13266 (22.5) 81276 (23.2) 46454 (21.8) 286172 (22.6)
2 12591 (21.4) 76874 (21.9) 44660 (20.9) 270343 (21.3)
3 12186 (20.7) 72400 (20.7) 41290 (19.4) 242733 (19.1)
4 11235 (19.1) 64829 (18.5) 41608 (19.5) 244115 (19.2)
5 (most deprived) 9595 (16.3) 55055 (15.7) 39191 (18.4) 224354 (17.7)
missing 31 (0.1) 158 (0.1) 197 (0.1) 1281 (0.1)
Ethnic group
White 49698 (84.4) 269071 (76.8) 171759 (80.5) 920950 (72.6)
Asian 1296 (2.2) 7971 (2.3) 7949 (3.7) 50370 (4.0)
Black 272 (0.5) 4789 (1.4) 1630 (0.8) 28255 (2.2)
Other 594 (1.0) 4529 (1.3) 2297 (1.0) 16705 (1.3)
Unknown 7044 (12.0) 64232 (18.0) 29765 (14.0) 252718 (20.0)
https://doi.org/10.1371/journal.pone.0254661.t001
Fig 1. Concordance in cancer recording for Aurum-linked people with psoriasis.
https://doi.org/10.1371/journal.pone.0254661.g001
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HES-identified cancer records. In CPRD Aurum-linked HES, 11,777 and 63,298 cancers
(excluding keratinocyte) were identified; 70.9% and 71.2% of these had a cancer record at the
same site in CPRD Aurum for people with psoriasis and comparisons respectively. Any site
record concordance was higher (84.0% psoriasis; 84.2% comparison). In patients with psoriasis
2,911 cancers (excluding keratinocyte) were identified in CPRD GOLD-linked HES and
15,124 cancers were identified in comparison patients. Of these, 67.3% (psoriasis) and 67.8%
(comparison) had a record at the same site in CPRD GOLD. Any cancer record concordance
for CPRD GOLD was 81.6% (psoriasis) and 81.6% (comparison). For site-specific cancers,
concordance between HES identified cancers and CPRD records was lowest for pancreatic,
lung and kidney cancer. In people with psoriasis, for any cancer (excluding keratinocyte)
record in HES, 40.7% (CPRD Aurum-linked HES) and 40.8% (CPRD GOLD-linked HES) also
had a cancer record in ONS mortality records.
Variation in concordance by psoriasis status. When considering same cancer site con-
cordance between source and comparator databases, notable differences were found between
psoriasis and comparison patients for two cancers. Of the liver cancers recorded in CPRD
Aurum-linked HES for people with psoriasis, 28% had no record in CPRD Aurum. In compar-
ison, for the psoriasis-free patients, 20% of liver cancer records were only found in HES. For
non-Hodgkin lymphoma (NHL), a greater proportion of cases were only found in CPRD
Aurum for people with psoriasis (16%) compared to comparison patients (10%). CPRD
GOLD results followed the same pattern and are included in the (S3 and S4 Tables).
Delays in recording cancer events between sources
There was little variation in the timing of recording of cancer events between people with
psoriasis and comparison patients or between CPRD GOLD-linked data and CPRD
Fig 2. Concordance in cancer recording for Aurum-linked comparison patients.
https://doi.org/10.1371/journal.pone.0254661.g002
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Aurum-linked data (Table 2). For records first identified in CPRD, between 75–79% were
identified within 3 months in HES. The large majority of records first identified in HES
were recorded in CPRD within 3 months (>90%), with less than 4% having a delay of over a
year. There was notable variation in the delay between records by cancer site, particularly
for records first identified in the CPRD. In records first identified in CPRD Aurum, the low-
est proportion of concordant records identified within three months was observed for kera-
tinocyte cancers, leukaemia, non-Hodgkin lymphoma and prostate cancer (Fig 3).
Variation in delay for records first identified in HES was less apparent, with only keratino-
cyte cancers having a notably lower proportion of concordant records within 3 months.
Results for the CPRD GOLD cohort were similar and are included in the (S4 Fig).
Risk factors for discordance in cancer recording
In CPRD Aurum, increased age was associated with discordance in cancer recording when
either CPRD or linked HES data was the source database, regardless of whether patients had
Table 2. Delay between same site cancer records in source and comparator database.
Delay to record in
comparison data
CPRD GOLD CPRD Aurum

















Within 3 months 859 (76.83) 941 (92.53) 4504 (78.37) 5121 (93.93) 3791(77.07) 3997 (94.18) 20516 (76.95) 21387 (94.15)
3 to 12 months 135 (12.08) 41 (4.03) 668 (11.62) 205 (3.76) 626 (12.73) 181 (4.26) 3285 (12.32) 872 (3.84)
Over year 124 (11.09) 35 (3.44) 575 (10.01) 126 (2.31) 502 (10.21) 66 (1.56) 2859 (10.72) 456 (2.01)
Total 1118 1017 5747 5452 4919 4244 26660 22715
https://doi.org/10.1371/journal.pone.0254661.t002
Fig 3. Delay between same site concordant record by cancer site for Aurum-linked data.
https://doi.org/10.1371/journal.pone.0254661.g003
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psoriasis (Table 3). Compared to those under 64, those aged 65–74 (OR 1.29, 95%CI: 1.23–
1.36) and over 75 (OR 2.06, 95%CI: 1.95–2.18) were more likely to have a record that only
appeared in HES. Only those aged over 75 were more likely than those aged less than 65 to
only have a record in CPRD Aurum (OR 1.43, 95%CI: 1.35–1.51). For both people with psoria-
sis and comparison patients, the odds of having a record only in the primary care records
reduced with increasing deprivation. In contrast, where HES was the source database, discor-
dance was more likely in the comparison cohort for those in more deprived areas. With
regards to temporality, later year of diagnosis was also associated with reduced discordance.
Factors associated with discordance in the CPRD GOLD cohort were similar and are pre-
sented in the (S5 Table).
Discussion
This study examined the concordance of cancer recording between primary care, hospital and
death registration data in people with and without psoriasis. Concordance of cancer records at
the same site between CPRD and HES was poor, with marked variation according to cancer
site. Though higher, concordance for any cancer record remained below 85%. The delay
between same-site records varied according to the database in which the cancer was first iden-
tified, with older age, time period and deprivation associated with discordance in reporting.
Concordance for cancer records of the same site differed according to the cancer site in
question and to the database in which the cancer was first identified. For cancers initially iden-
tified in the CPRD, same-site concordance in HES was notably lower for keratinocyte cancers
and malignant melanoma. Conversely, for cancers initially identified in HES, same-site
Table 3. Multivariable-adjusted odds of non-concordance according to covariates in CPRD-Aurum and linked HES data.
Psoriasis—Aurum Source Psoriasis—HES Source Comparison—Aurum Source Comparison—HES Source
Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI Odds Ratio 95% CI
Age categories
Under 64 1.00 reference 1.00 reference 1.00 reference 1.00 reference
65 to 74 0.93 0.83 1.05 1.22 1.09 1.37 1.01 0.96 1.07 1.29 1.23 1.36
Over 75 1.38 1.21 1.58 1.80 1.59 2.05 1.43 1.35 1.51 2.06 1.95 2.18
Gender
Male 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Female 1.09 0.98 1.20 1.06 0.96 1.18 1.02 0.98 1.07 1.04 1.00 1.09
Deprivation
1 (least deprived) 1.00 reference 1.00 reference 1.00 reference 1.00 reference
2 0.92 0.80 1.06 0.83 0.72 0.96 0.88 0.83 0.94 0.98 0.91 1.04
3 0.79 0.68 0.92 0.82 0.70 0.96 0.81 0.76 0.86 1.10 1.03 1.17
4 0.75 0.65 0.88 1.07 0.92 1.24 0.73 0.68 0.78 1.17 1.09 1.25
5 (most deprived) 0.63 0.53 0.75 1.03 0.88 1.20 0.63 0.59 0.68 1.29 1.20 1.38
Period
1998/2000 1.00 reference 1.00 reference 1.00 reference 1.00 reference
2001/2003 0.71 0.50 1.00 0.86 0.59 1.26 0.75 0.63 0.89 0.80 0.68 0.94
2004/2006 0.40 0.29 0.56 0.52 0.36 0.75 0.63 0.54 0.75 0.56 0.48 0.65
2007/2009 0.34 0.25 0.47 0.57 0.40 0.80 0.55 0.47 0.65 0.51 0.44 0.60
2010/2012 0.36 0.27 0.49 0.58 0.41 0.82 0.55 0.47 0.64 0.47 0.40 0.55
2013/2015 0.38 0.28 0.52 0.57 0.41 0.80 0.60 0.51 0.70 0.49 0.42 0.57
2016/2018 0.57 0.43 0.77 0.60 0.43 0.85 0.84 0.72 0.99 0.57 0.49 0.66
https://doi.org/10.1371/journal.pone.0254661.t003
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concordance in the CPRD was lowest for pancreatic, lung and kidney cancers. Previously sug-
gested plausible explanations for lower same-site concordance include the use of non-specific
cancer diagnostic codes, death shortly following hospital admission for cancer, and death from
cancer prior to hospitalisation [26], with the latter two explanations supported by increased
likelihood of discordance in older patients. With regards to keratinocyte cancers specifically,
high discordance between CPRD and HES records likely arises as appropriately trained pri-
mary care physicians are able to excise lesions without referral to secondary care [27]. As
lower concordance of same-site records suggests a potential for poor outcome ascertainment
in studies utilising only one data source, these results support the need to link primary and sec-
ondary care data sources in CPRD studies of cancer occurrence, especially those considering
site-specific cancers.
Differences in concordance between people with and without psoriasis were present for
some site-specific cancers, with implications for studies considering associations between pso-
riasis and cancer. For NHL identified in HES, site-specific concordance within CPRD was
lower for people with psoriasis compared to those without. As cutaneous T-cell lymphoma
(CTCL), a variant of NHL, clinically manifests in a manner which mimics psoriasis [28], it is
possible that people with CTCL are misdiagnosed as having psoriasis in primary care. Referral
to specialist hospital services would likely result in an accurate CTCL diagnosis and a conse-
quential discordant cancer record. Furthermore, in people with psoriasis, CPRD identified
NHL records were also more commonly discordant–likely resulting from patients receiving an
incorrect CTCL diagnosis in primary care, which is then correctly identified as psoriasis in sec-
ondary care. The link between psoriasis and lymphoma has received significant focus in previ-
ous work [10, 11, 29] and these results suggest caution in the interpretation of these findings.
Studies utilising only primary or secondary care records that do not differentiate between
NHL variants are likely to over-estimate the risk of NHL through the aforementioned misclas-
sification of CTCL cases in psoriasis patients.
There was also heterogeneity in the recording of liver cancer cases between people with and
without psoriasis, with a greater proportion of liver cancer cases only identified in HES for
people with psoriasis. It is plausible that this discordance arises as psoriasis patients have
higher liver cancer mortality and therefore die before a record is made in the CPRD–an argu-
ment supported by increased heavy drinking in people with psoriasis [30] and the suggested
increased mortality in alcohol-associated liver cancer [31]. Under this explanation, studies that
only use primary care records may underestimate the association between psoriasis and liver
cancer.
Beyond psoriasis, age, deprivation and time period were all predictors of discordance. As
noted previously, increasing age was associated with an increased probability of having a dis-
cordant record–likely resulting from cancer death prior to a record being made in the compar-
ison data source. For records first identified in the CPRD, increasing deprivation was
associated with lower discordance. Rather than suggesting improved recording practices in
more deprived areas, it is likely that this relationship is explained by the increased incidence of
the most commonly discordant cancers, such as keratinocyte cancers [32], malignant mela-
noma [33] and prostate cancer [34], in less deprived areas. With regards to time, reduced dis-
cordance in later periods is suggestive of improved data recording, as noted for lifestyle and
demographic factors in previous works [20].
To our knowledge, this is the first study to consider the concordance of cancer recording
between CPRD Aurum and linked HES data, and the inclusion of both GOLD and Aurum
within the study allows cross-validation between the two databases. A potential limitation, as
in any study of concordance between EHRs, are discrepancies in coding dictionaries. How-
ever, code list review by multiple clinicians was carried out to minimise any issues.
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In conclusion, the use of primary care or hospital data in isolation to determine cancer
events is likely to be inadequate, particularly when considering certain site-specific cancers. In
addition, these inadequacies may be exacerbated through improper consideration of impor-
tant predictors of discordance. As such, the use of linked electronic health records, with appro-
priate covariate consideration, is strongly advisable in studies of cancer risk as a means of
improving outcome ascertainment.
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